Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Approval of Aducanumab
Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s […]
U.S. FDA Approves Prevnar 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved […]
Half a Million COVID Jabs Booked in ‘Glastonbury Rush’ This Morning
The NHS saw a welcome surge in demand for vaccines this morning as half a […]
Carthera’s Sonocloud Technology Enhances the Efficacy of Immunotherapies for the Treatment of Brain Tumors
CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain […]
Camber Pharma Launches Generic Kaletra
Camber Pharmaceuticals is pleased to announce that it has launched Lopinavir and RitonavirTablets, which is […]
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Novartis Announces Iptacopan Met Phase II Study Primary Endpoint in Rare Kidney Disease IgA Nephropathy (IgAN)
Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, […]
Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre
Vaccination appointments are available for residents who are eligible at the Riverside Vaccination Centre in […]
‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges
Doctors are now confident they can detect and treat the rare blood clotting syndrome associated […]
Tollys Presents Scientific Data Supporting Preclinical Proof of Concept for TL-532, Its Cancer Immunotherapy Drug Candidate
Tollys, a biopharmaceutical company developing TL-532, the first synthetic specific agonist of Toll-like Receptor 3 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more